Analysts Set X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) PT at $11.25

Shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) have earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $11.25.

Several analysts have issued reports on the stock. Leerink Partners started coverage on shares of X4 Pharmaceuticals in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $12.00 target price on the stock. Wells Fargo & Company began coverage on shares of X4 Pharmaceuticals in a report on Friday, July 10th. They issued an “overweight” rating and a $11.00 price target on the stock. Finally, Weiss Ratings downgraded X4 Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th.

X4 Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ XFOR opened at $4.16 on Wednesday. X4 Pharmaceuticals has a 52 week low of $2.80 and a 52 week high of $4.83. The business has a 50-day simple moving average of $4.09 and a two-hundred day simple moving average of $3.98. The company has a quick ratio of 11.02, a current ratio of 11.30 and a debt-to-equity ratio of 0.49. The company has a market cap of $412.46 million, a P/E ratio of -3.47 and a beta of 0.37.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.05. X4 Pharmaceuticals had a negative net margin of 568.80% and a negative return on equity of 63.05%. The firm had revenue of $8.81 million for the quarter, compared to the consensus estimate of $2.42 million. Research analysts anticipate that X4 Pharmaceuticals will post -0.71 earnings per share for the current fiscal year.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, Chairman Adam R. Craig sold 47,436 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $4.44, for a total value of $210,615.84. Following the transaction, the chairman directly owned 328,651 shares in the company, valued at approximately $1,459,210.44. This represents a 12.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO David Kirske sold 8,543 shares of the firm’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $4.26, for a total transaction of $36,393.18. Following the completion of the sale, the chief financial officer directly owned 167,750 shares in the company, valued at $714,615. This represents a 4.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 80,555 shares of company stock valued at $356,126 in the last 90 days. Corporate insiders own 1.13% of the company’s stock.

Hedge Funds Weigh In On X4 Pharmaceuticals

A number of institutional investors have recently made changes to their positions in XFOR. Bank of America Corp DE lifted its holdings in shares of X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after acquiring an additional 22,485 shares during the last quarter. Rhumbline Advisers raised its position in X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock valued at $44,000 after purchasing an additional 9,690 shares in the last quarter. Jane Street Group LLC lifted its stake in X4 Pharmaceuticals by 112.5% during the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock worth $185,000 after purchasing an additional 51,544 shares during the last quarter. Vanguard Group Inc. lifted its stake in X4 Pharmaceuticals by 77.0% during the third quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after purchasing an additional 178,593 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new position in shares of X4 Pharmaceuticals in the 3rd quarter worth about $47,000. Institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.